Found: 21
Select item for more details and to access through your institution.
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 2, p. 171, doi. 10.1002/jcph.1941
- By:
- Publication type:
- Article
Effects of Enzastaurin and Its Metabolites on the QT Interval in Cancer Patients.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 1, p. 101, doi. 10.1002/jcph.573
- By:
- Publication type:
- Article
Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-β Inhibitor, in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2007, v. 47, n. 9, p. 1138, doi. 10.1177/0091270007304775
- By:
- Publication type:
- Article
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study†.
- Published in:
- Neuro-Oncology, 2010, v. 12, n. 6, p. 608, doi. 10.1093/neuonc/nop070
- By:
- Publication type:
- Article
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
- Published in:
- Neuro-Oncology, 2010, v. 12, n. 2, p. 181, doi. 10.1093/neuonc/nop042
- By:
- Publication type:
- Article
Pediatric Dose Selection and Utility of PBPK in Determining Dose.
- Published in:
- AAPS Journal, 2018, v. 20, n. 2, p. 1, doi. 10.1208/s12248-018-0187-8
- By:
- Publication type:
- Article
Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 4, p. 240, doi. 10.1002/psp4.12394
- By:
- Publication type:
- Article
Correction to: Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
- Published in:
- Pharmaceutical Research, 2018, v. 35, n. 12, p. 1, doi. 10.1007/s11095-018-2516-0
- By:
- Publication type:
- Article
Time to Rethink the Current Paradigm for Assessing Kidney Function in Drug Development and Beyond.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 5, p. 946, doi. 10.1002/cpt.2489
- By:
- Publication type:
- Article
Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 5, p. 707, doi. 10.1007/s00280-022-04434-2
- By:
- Publication type:
- Article
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 6, p. 921, doi. 10.1007/s00280-021-04344-9
- By:
- Publication type:
- Article
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
- Published in:
- 2015
- By:
- Publication type:
- journal article
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 1, p. 163, doi. 10.1007/s10637-020-00975-6
- By:
- Publication type:
- Article
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 2, p. 419, doi. 10.1007/s10637-019-00776-6
- By:
- Publication type:
- Article
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 4, p. 356, doi. 10.1007/s10637-008-9193-5
- By:
- Publication type:
- Article
Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 2, p. 144, doi. 10.1002/cpdd.847
- By:
- Publication type:
- Article
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 3, p. 283, doi. 10.1007/s11523-022-00888-9
- By:
- Publication type:
- Article
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 2, p. 233, doi. 10.1007/s00280-008-0853-0
- By:
- Publication type:
- Article
Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
- Published in:
- 2016
- By:
- Publication type:
- journal article